Serum biomarkers of hypoxic-ischemic brain injury

0580552 - FGÚ 2024 RIV CZ eng J - Článek v odborném periodiku
Tefr Faridová, A. - Heřman, H. - Danačíková, Šárka - Svoboda, Jan - Otáhal, Jakub
Serum biomarkers of hypoxic-ischemic brain injury.
Physiological Research. Roč. 72, Suppl.5 (2023), S461-S474. ISSN 0862-8408. E-ISSN 1802-9973
Grant CEP: GA MŠMT(CZ) LX22NPO5107
Institucionální podpora: RVO:67985823
Klíčová slova: brain injury * serum biomarkers * neuron-specific enolase * ubiquitin carboxy-terminal hydrolase L1 * S100 calcium-binding protein beta * glial fibrillary acidic protein * high-mobility-groupprotein-box-1
Obor OECD: Neurosciences (including psychophysiology
Impakt faktor: 2.1, rok: 2022
Způsob publikování: Open access
https://www.biomed.cas.cz/physiolres/pdf/72/72_S461.pdf

Brain injury is a multifaceted condition arising from nonspecific damage to nervous tissue. The resulting cognitive developmental impairments reverberate through patients' lives, affecting their families, and even the broader economic landscape. The significance of early brain injury detection lies in its potential to stave off severe consequences and enhance the effectiveness of tailored therapeutic interventions. While established methods like neuroimaging and neurophysiology serve as valuable diagnostic tools, their demanding nature restricts their accessibility, particularly in scenarios such as small hospitals, nocturnal or weekend shifts, and cases involving unstable patients. Hence, there is a pressing need for more accessible and efficient diagnostic avenues. Among the spectrum of brain injuries, hypoxic-ischemic encephalopathy stands out as a predominant affliction in the pediatric population. Diagnosing brain injuries in newborns presents challenges due to the subjective nature of assessments like Apgar scores and the inherent uncertainty in neurological examinations. In this context, methods like magnetic resonance and ultrasound hold recommendations for more accurate diagnosis. Recognizing the potential of serum biomarkers derived from blood samples, this paper underscores their promise as a more expedient and resource-efficient means of assessing brain injuries. The review compiles current insights into serum biomarkers, drawing from experiments conducted on animal models as well as human brain pathologies. The authors aim to elucidate specific characteristics, temporal profiles, and the available corpus of experimental and clinical data for serum biomarkers specific to brain injuries. These include neuronspecific enolase (NSE), ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), S100 calcium-binding protein beta (S100B), glial fibrillary acidic protein (GFAP), and high-mobility-group-proteinbox-1 (HMGB1). This comprehensive endeavor contributes to advancing the understanding of brain injury diagnostics and potential avenues for therapeutic intervention.
Trvalý link: https://hdl.handle.net/11104/0349312